FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383065767> ?p ?o ?g. }

• W4383065767 endingPage "1106" @default.
• W4383065767 startingPage "1105" @default.
• W4383065767 abstract "Lyme disease (Lyme borreliosis) is a tick-borne bacterial infection that occurs in the temperate climates of North America and Eurasia. Treatment with antibiotics is effective only in the early stages of infection. Although the first human Lyme disease vaccine (LYMErix by SmithKline Beecham, Pittsburgh, PA, USA) was marketed and distributed in the USA from 1998 until 2002, it was discontinued and no vaccine is currently available. 1 Steere AC Sikand VK Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med. 1998; 339: 209-215 Crossref PubMed Scopus (580) Google Scholar , 2 Sigal LH Zahradnik JM Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med. 1998; 339: 216-222 Crossref PubMed Scopus (332) Google Scholar , 3 Wressnigg N Pöllabauer E-M Aichinger G et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis. 2013; 13: 680-689 Summary Full Text Full Text PDF PubMed Scopus (57) Google Scholar In The Lancet Infectious Diseases, Nicole Bézay and colleagues report the results of a randomised, phase 1, clinical trial in healthy adults immunised with Valneva's novel, multivalent outer surface protein A (OspA) subunit vaccine called VLA15. 4 Bézay N Hochreiter R Kadlecek V et al. Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults. Lancet Infect Dis. 2023; (published online July 4.)https://doi.org/10.1016/S1473-3099(23)00210-4 Google Scholar Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adultsThis novel multivalent vaccine candidate against Lyme borreliosis was safe and immunogenic and paves the way to further clinical development. Full-Text PDF" @default.
• W4383065767 created "2023-07-05" @default.
• W4383065767 creator A5042444252 @default.
• W4383065767 creator A5091549922 @default.
• W4383065767 date "2023-10-01" @default.
• W4383065767 modified "2023-10-17" @default.
• W4383065767 title "VLA15, a new global Lyme disease vaccine undergoes clinical trials" @default.
• W4383065767 cites W2019159555 @default.
• W4383065767 cites W2071985786 @default.
• W4383065767 cites W2105337959 @default.
• W4383065767 cites W2123049890 @default.
• W4383065767 cites W2123757128 @default.
• W4383065767 cites W2320088211 @default.
• W4383065767 cites W2337700516 @default.
• W4383065767 cites W2964596603 @default.
• W4383065767 cites W4383101079 @default.
• W4383065767 doi "https://doi.org/10.1016/s1473-3099(23)00312-2" @default.
• W4383065767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37419127" @default.
• W4383065767 hasPublicationYear "2023" @default.
• W4383065767 type Work @default.
• W4383065767 citedByCount "0" @default.
• W4383065767 crossrefType "journal-article" @default.
• W4383065767 hasAuthorship W4383065767A5042444252 @default.
• W4383065767 hasAuthorship W4383065767A5091549922 @default.
• W4383065767 hasConcept C159047783 @default.
• W4383065767 hasConcept C159654299 @default.
• W4383065767 hasConcept C203014093 @default.
• W4383065767 hasConcept C22070199 @default.
• W4383065767 hasConcept C2777553296 @default.
• W4383065767 hasConcept C2779159148 @default.
• W4383065767 hasConcept C2780868878 @default.
• W4383065767 hasConcept C71924100 @default.
• W4383065767 hasConceptScore W4383065767C159047783 @default.
• W4383065767 hasConceptScore W4383065767C159654299 @default.
• W4383065767 hasConceptScore W4383065767C203014093 @default.
• W4383065767 hasConceptScore W4383065767C22070199 @default.
• W4383065767 hasConceptScore W4383065767C2777553296 @default.
• W4383065767 hasConceptScore W4383065767C2779159148 @default.
• W4383065767 hasConceptScore W4383065767C2780868878 @default.
• W4383065767 hasConceptScore W4383065767C71924100 @default.
• W4383065767 hasIssue "10" @default.
• W4383065767 hasLocation W43830657671 @default.
• W4383065767 hasLocation W43830657672 @default.
• W4383065767 hasOpenAccess W4383065767 @default.
• W4383065767 hasPrimaryLocation W43830657671 @default.
• W4383065767 hasRelatedWork W1574807761 @default.
• W4383065767 hasRelatedWork W1938211295 @default.
• W4383065767 hasRelatedWork W2018531760 @default.
• W4383065767 hasRelatedWork W2041807283 @default.
• W4383065767 hasRelatedWork W2076721603 @default.
• W4383065767 hasRelatedWork W2104069948 @default.
• W4383065767 hasRelatedWork W2354693513 @default.
• W4383065767 hasRelatedWork W2896265749 @default.
• W4383065767 hasRelatedWork W4311815916 @default.
• W4383065767 hasRelatedWork W2523584416 @default.
• W4383065767 hasVolume "23" @default.
• W4383065767 isParatext "false" @default.
• W4383065767 isRetracted "false" @default.
• W4383065767 workType "article" @default.